Market

Trends in Cyxone’s segment

Cyxone believes that growth in the MS market is limited by currently available drugs’ sometimes severe side effects, that some treatments are only directed to certain types of MS sufferers, (RRMS patients), and that drugs are often administered by injection. In the past 10-year period, several large drug companies have developed drugs that can be taken as tablets, but their side effects still prohibit their wider use by MS patients. Several biological drugs with powerful pharmacological effects have also been developed, although these are associated with serious side effects. The trend is towards attempting to identify drugs with fewer side effects med, which can therefore be administered over longer periods, even to non-RRMS patients, in tablet form. It should also be noted that established drug companies on the MS market are, due to patents for many existing MS drugs are set to expire, highly focused on identifying new products that can replace old products to protect and increase their market share.

Market potential

Cyxone’s potential market for T20K is considerable, and is expected to grow in the coming years. In Sweden, some 18,000 people currently have MS, and an estimated 2.5 billion people are affected by the disease worldwide. The value of the MS market is projected to increase from USD 17.2 billion in 2014 to approximately USD 20 billion in 2024, despite several leading products, (Copaxone, Rebif, and Betaseron), losing patent protection during this period.

A new drug in tablet form that can slow the development of MS, and one that is at the same time sufficiently “kind” to the body that it is possible to be taken throughout a patient’s life could replace many of the drugs that are currently available.

Competitors

The ten best selling drugs for MS are:

  • Copaxone
  • Avonex
  • Rebif
  • Gilenya Tysabri
  • Betaseron
  • Tecfidera
  • Ampyra
  • P. Acthar Gel
  • Aubagio

The four best-selling MS drugs, (Gilenya, Tecfidera, Avonex, and Copaxone), generated combined sales of around USD 12 billion in 2013. Top sellers such as Copaxone, Rebif, and Betaseron are older drugs that are no longer patent protected.